AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
AIM ImmunoTech Inc. (AIM)
Company Research
Source: Yahoo! Finance
Insurance Coverage Issue: $2.5 million secondary layer of coverage from a D&O insurance company not yet paid. R&D Investment: Over $200,000 invested in R&D experiments to optimize Ampligen production. Cost Savings: Estimated $2 million savings in method transfer and validation process, with future cost reductions of about $200,000 per batch of Ampligen. Warning! GuruFocus has detected 6 Warning Signs with AIM. Release Date: November 15, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript AIM ImmunoTech Inc ( AIM ) reported positive preliminary data from the Phase Ib/II DURIPANC study, showing promising results in treating late-stage metastatic pancreatic cancer. The company announced statistically significant data supporting Ampligen as a potential therapeutic for moderate to severe post-COVID conditions of fatigue. AIM ImmunoTech Inc ( AIM ) continues to expand its intellectual property portfolio, including a new p
Show less
Read more
Impact Snapshot
Event Time:
AIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AIM alerts
High impacting AIM ImmunoTech Inc. news events
Weekly update
A roundup of the hottest topics
AIM
News
- Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM BoardPR Newswire
- AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer [Yahoo! Finance]Yahoo! Finance
- AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of CancerGlobeNewswire
- Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board [Yahoo! Finance]Yahoo! Finance
- Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM BoardGlobeNewswire
AIM
Sec Filings
- 11/21/24 - Form 4
- 11/21/24 - Form 4
- 11/20/24 - Form DFAN14A
- AIM's page on the SEC website